Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2013

View Archived Issues

Investigators optogenetically delay seizures in animal models

Mouse model of congenital indifference to pain created

Copeptin is a marker of future stroke risk after transient ischemic attack

Diuretic and natriuretic effect of LCZ-696 in patients with hypertension

Researchers discover novel genetic biomarker for several human diseases

Expression of three genes predicts tolerance in renal transplant recipients

Millennium presents preclinical results for novel antibody-drug conjugate MLN-0264

Bio-Path opens enrollment in sixth cohort of phase I liposomal GRB2 trial

Second Genome and Janssen enter microbiome drug discovery agreement

Novavax develops novel coronavirus vaccine candidate

Oculus Innovative Sciences enters into agreement with Ruthigen

Esperion Therapeutics reports results from phase II study of ETC-1002

DMC recommends continuation of phase II ICT-107 trial

Eisai launches Belviq for chronic weight management

Researchers at Glenmark Pharmaceuticals patent new MPGES-1 inhibitors

Xention prepares new potassium channel blockers

Racotumomab, which improves lung cancer survival rate, soon to be available in Argentina

Gilead Sciences' receives priority review for sofosbuvir NDA

First compound from Eisai and Quintiles' anticancer collaboration demonstrates proof of concept

AstraZeneca signs definitive agreement to acquire Pearl Therapeutics

FDA approves Fluzone Quadrivalent influenza vaccine

EMA approves RoActemra for polyarticular juvenile idiopathic arthritis

Merck & Co. discloses novel GPR119 receptor agonists

Cephalon divulges new protein kinase inhibitors

Scientists at Astellas Pharma present novel DAAO inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...